These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35091044)

  • 1. Editorial commentary: Exciting new therapies for familial hypercholesterolemia, but we can also make better use of some old ones.
    Walsh JP
    Trends Cardiovasc Med; 2023 Apr; 33(3):180-181. PubMed ID: 35091044
    [No Abstract]   [Full Text] [Related]  

  • 2. LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
    Santos RD; Cuchel M
    Circulation; 2024 Jan; 149(5):363-366. PubMed ID: 38285739
    [No Abstract]   [Full Text] [Related]  

  • 3. The treatment of heterozygous familial hypercholesterolemia - a local perspective.
    Bułdak Ł
    Endokrynol Pol; 2021; 72(3):189-190. PubMed ID: 34292576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial Commentary: What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?
    Brunham LR; Mancini GBJ
    Trends Cardiovasc Med; 2021 May; 31(4):216-217. PubMed ID: 32407995
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms.
    Kallapur A; Sallam T
    Trends Cardiovasc Med; 2023 Apr; 33(3):170-179. PubMed ID: 34968676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
    Rallidis LS; Liberopoulos EN; Vlachopoulos C; Skoumas I; Kolovou G; Anastasiou G; Dima I; Tousoulis D; Iliodromitis E
    Atherosclerosis; 2020 Sep; 309():67-69. PubMed ID: 32859385
    [No Abstract]   [Full Text] [Related]  

  • 8. Evinacumab for Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
    N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 11. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

  • 12. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
    N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe xanthomatosis in heterozygous familial hypercholesterolemia.
    Aljenedil S; Ruel I; Watters K; Genest J
    J Clin Lipidol; 2018; 12(4):872-877. PubMed ID: 29778561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.
    Reeskamp LF; Millar JS; Wu L; Jansen H; van Harskamp D; Schierbeek H; Gipe DA; Rader DJ; Dallinga-Thie GM; Hovingh GK; Cuchel M
    Arterioscler Thromb Vasc Biol; 2021 May; 41(5):1753-1759. PubMed ID: 33691480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolocumab in the management of children <10 years of age affected by homozygous familial hypercholesterolemia.
    Buonuomo PS; Mastrogiorgio G; Leone G; Rana I; Gonfiantini MV; Macchiaiolo M; Vecchio D; Gnazzo M; Bartuli A
    Atherosclerosis; 2021 May; 324():148-150. PubMed ID: 33824001
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
    Won JI; Zhang J; Tecson KM; McCullough PA
    Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.
    Kolovou G; Vasiliadis I; Gontoras N; Kolovou V; Hatzigeorgiou G
    Cardiovasc Ther; 2015 Apr; 33(2):71-8. PubMed ID: 25604780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant sterol supplementation on top of lipid-lowering therapies in familial hypercholesterolemia.
    Machado VA; Fonseca FA; Fonseca HA; Malina DT; Fonzar WT; Barbosa SA; Santana JM; Izar MC
    Int J Cardiol; 2015 Apr; 184():570-572. PubMed ID: 25767019
    [No Abstract]   [Full Text] [Related]  

  • 20. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.